nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—hypertension—metabolic syndrome X	0.925	1	CtDrD
Eprosartan—AGTR1—artery—metabolic syndrome X	0.0041	0.222	CbGeAlD
Eprosartan—AGTR1—endothelium—metabolic syndrome X	0.00346	0.187	CbGeAlD
Eprosartan—AGTR1—blood vessel—metabolic syndrome X	0.00319	0.173	CbGeAlD
Eprosartan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—EPHX2—metabolic syndrome X	0.0024	0.064	CbGpPWpGaD
Eprosartan—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—EPHX2—metabolic syndrome X	0.00216	0.0575	CbGpPWpGaD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—NR1I3—metabolic syndrome X	0.00204	0.0543	CbGpPWpGaD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—NR1I2—metabolic syndrome X	0.00186	0.0496	CbGpPWpGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—ACE—metabolic syndrome X	0.00182	0.0484	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H3—metabolic syndrome X	0.0016	0.0426	CbGpPWpGaD
Eprosartan—Toothache—Metformin—metabolic syndrome X	0.00144	0.0834	CcSEcCtD
Eprosartan—AGTR1—cardiovascular system—metabolic syndrome X	0.00142	0.0771	CbGeAlD
Eprosartan—AGTR1—kidney—metabolic syndrome X	0.00139	0.0755	CbGeAlD
Eprosartan—Losartan—ACE—metabolic syndrome X	0.00139	0.709	CrCbGaD
Eprosartan—AGTR1—adipose tissue—metabolic syndrome X	0.00126	0.068	CbGeAlD
Eprosartan—ABCC2—Constitutive Androstane Receptor Pathway—NR1I3—metabolic syndrome X	0.00123	0.0327	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—metabolic syndrome X	0.00117	0.0312	CbGpPWpGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—AGT—metabolic syndrome X	0.00115	0.0307	CbGpPWpGaD
Eprosartan—CYP2C9—Tamoxifen metabolism—FMO3—metabolic syndrome X	0.00112	0.0298	CbGpPWpGaD
Eprosartan—Rigors—Metformin—metabolic syndrome X	0.00108	0.0621	CcSEcCtD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—metabolic syndrome X	0.00107	0.0285	CbGpPWpGaD
Eprosartan—ABCC2—kidney—metabolic syndrome X	0.00101	0.0546	CbGeAlD
Eprosartan—AGTR1—liver—metabolic syndrome X	0.000881	0.0477	CbGeAlD
Eprosartan—AGTR1—ACE Inhibitor Pathway—NOS3—metabolic syndrome X	0.000845	0.0225	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 trafficking events—SLC2A4—metabolic syndrome X	0.00076	0.0202	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H3—metabolic syndrome X	0.000702	0.0187	CbGpPWpGaD
Eprosartan—CYP2C9—cardiovascular system—metabolic syndrome X	0.000686	0.0371	CbGeAlD
Eprosartan—ABCC2—liver—metabolic syndrome X	0.000637	0.0345	CbGeAlD
Eprosartan—Migraine—Metformin—metabolic syndrome X	0.000627	0.0362	CcSEcCtD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—metabolic syndrome X	0.000615	0.0164	CbGpPWpGaD
Eprosartan—Losartan—ALB—metabolic syndrome X	0.000569	0.291	CrCbGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—TGFB1—metabolic syndrome X	0.000559	0.0149	CbGpPWpGaD
Eprosartan—CYP2C9—Constitutive Androstane Receptor Pathway—NR1I3—metabolic syndrome X	0.000539	0.0144	CbGpPWpGaD
Eprosartan—Angina pectoris—Metformin—metabolic syndrome X	0.000536	0.031	CcSEcCtD
Eprosartan—Sweating increased—Metformin—metabolic syndrome X	0.000536	0.031	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—metabolic syndrome X	0.000514	0.0137	CbGpPWpGaD
Eprosartan—Upper respiratory tract infection—Metformin—metabolic syndrome X	0.000512	0.0296	CcSEcCtD
Eprosartan—CYP2C9—Arachidonic acid metabolism—EPHX2—metabolic syndrome X	0.000498	0.0133	CbGpPWpGaD
Eprosartan—Neuropathy peripheral—Metformin—metabolic syndrome X	0.000481	0.0278	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—metabolic syndrome X	0.00047	0.0125	CbGpPWpGaD
Eprosartan—Bradycardia—Metformin—metabolic syndrome X	0.000449	0.0259	CcSEcCtD
Eprosartan—Rhinitis—Metformin—metabolic syndrome X	0.000442	0.0255	CcSEcCtD
Eprosartan—Oedema peripheral—Metformin—metabolic syndrome X	0.000434	0.0251	CcSEcCtD
Eprosartan—AGTR1—Arf6 trafficking events—INS—metabolic syndrome X	0.000427	0.0114	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—metabolic syndrome X	0.000426	0.0114	CbGpPWpGaD
Eprosartan—CYP2C9—liver—metabolic syndrome X	0.000424	0.023	CbGeAlD
Eprosartan—Chills—Metformin—metabolic syndrome X	0.000396	0.0229	CcSEcCtD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—FMO3—metabolic syndrome X	0.000391	0.0104	CbGpPWpGaD
Eprosartan—ABCC2—ABC-family proteins mediated transport—APOA1—metabolic syndrome X	0.000382	0.0102	CbGpPWpGaD
Eprosartan—Flatulence—Metformin—metabolic syndrome X	0.000378	0.0218	CcSEcCtD
Eprosartan—Muscle spasms—Metformin—metabolic syndrome X	0.000369	0.0213	CcSEcCtD
Eprosartan—Tremor—Metformin—metabolic syndrome X	0.00036	0.0208	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—metabolic syndrome X	0.000356	0.0095	CbGpPWpGaD
Eprosartan—Ill-defined disorder—Metformin—metabolic syndrome X	0.000356	0.0206	CcSEcCtD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—metabolic syndrome X	0.000352	0.00938	CbGpPWpGaD
Eprosartan—Malaise—Metformin—metabolic syndrome X	0.000346	0.02	CcSEcCtD
Eprosartan—Syncope—Metformin—metabolic syndrome X	0.000344	0.0199	CcSEcCtD
Eprosartan—Palpitations—Metformin—metabolic syndrome X	0.000339	0.0196	CcSEcCtD
Eprosartan—Loss of consciousness—Metformin—metabolic syndrome X	0.000337	0.0195	CcSEcCtD
Eprosartan—Chest pain—Metformin—metabolic syndrome X	0.000327	0.0189	CcSEcCtD
Eprosartan—Myalgia—Metformin—metabolic syndrome X	0.000327	0.0189	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—G6PD—metabolic syndrome X	0.000325	0.00866	CbGpPWpGaD
Eprosartan—Discomfort—Metformin—metabolic syndrome X	0.000323	0.0186	CcSEcCtD
Eprosartan—Shock—Metformin—metabolic syndrome X	0.000308	0.0178	CcSEcCtD
Eprosartan—Thrombocytopenia—Metformin—metabolic syndrome X	0.000307	0.0177	CcSEcCtD
Eprosartan—Hyperhidrosis—Metformin—metabolic syndrome X	0.000303	0.0175	CcSEcCtD
Eprosartan—Anorexia—Metformin—metabolic syndrome X	0.000299	0.0172	CcSEcCtD
Eprosartan—Hypotension—Metformin—metabolic syndrome X	0.000293	0.0169	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—HTR2C—metabolic syndrome X	0.00029	0.00774	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—MTNR1B—metabolic syndrome X	0.000288	0.00768	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Metformin—metabolic syndrome X	0.000285	0.0165	CcSEcCtD
Eprosartan—Paraesthesia—Metformin—metabolic syndrome X	0.000281	0.0162	CcSEcCtD
Eprosartan—Dyspnoea—Metformin—metabolic syndrome X	0.000279	0.0161	CcSEcCtD
Eprosartan—Somnolence—Metformin—metabolic syndrome X	0.000278	0.0161	CcSEcCtD
Eprosartan—Dyspepsia—Metformin—metabolic syndrome X	0.000276	0.0159	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—GHRL—metabolic syndrome X	0.000275	0.00733	CbGpPWpGaD
Eprosartan—Decreased appetite—Metformin—metabolic syndrome X	0.000272	0.0157	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—GHRL—metabolic syndrome X	0.000272	0.00724	CbGpPWpGaD
Eprosartan—Fatigue—Metformin—metabolic syndrome X	0.00027	0.0156	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—metabolic syndrome X	0.00027	0.00719	CbGpPWpGaD
Eprosartan—Constipation—Metformin—metabolic syndrome X	0.000268	0.0155	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2C—metabolic syndrome X	0.00026	0.00692	CbGpPWpGaD
Eprosartan—Feeling abnormal—Metformin—metabolic syndrome X	0.000258	0.0149	CcSEcCtD
Eprosartan—Gastrointestinal pain—Metformin—metabolic syndrome X	0.000256	0.0148	CcSEcCtD
Eprosartan—Urticaria—Metformin—metabolic syndrome X	0.000249	0.0144	CcSEcCtD
Eprosartan—Abdominal pain—Metformin—metabolic syndrome X	0.000248	0.0143	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—MTNR1B—metabolic syndrome X	0.000247	0.00658	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—metabolic syndrome X	0.000246	0.00656	CbGpPWpGaD
Eprosartan—Asthenia—Metformin—metabolic syndrome X	0.000225	0.013	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—HTR2C—metabolic syndrome X	0.000224	0.00598	CbGpPWpGaD
Eprosartan—Pruritus—Metformin—metabolic syndrome X	0.000222	0.0128	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—metabolic syndrome X	0.00022	0.00586	CbGpPWpGaD
Eprosartan—Diarrhoea—Metformin—metabolic syndrome X	0.000214	0.0124	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—FMO3—metabolic syndrome X	0.000208	0.00554	CbGpPWpGaD
Eprosartan—Dizziness—Metformin—metabolic syndrome X	0.000207	0.012	CcSEcCtD
Eprosartan—CYP2C9—Metapathway biotransformation—FMO3—metabolic syndrome X	0.000205	0.00547	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CNR1—metabolic syndrome X	0.000201	0.00537	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CCL5—metabolic syndrome X	0.000199	0.00531	CbGpPWpGaD
Eprosartan—Vomiting—Metformin—metabolic syndrome X	0.000199	0.0115	CcSEcCtD
Eprosartan—Rash—Metformin—metabolic syndrome X	0.000197	0.0114	CcSEcCtD
Eprosartan—Dermatitis—Metformin—metabolic syndrome X	0.000197	0.0114	CcSEcCtD
Eprosartan—Headache—Metformin—metabolic syndrome X	0.000196	0.0113	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR2C—metabolic syndrome X	0.000192	0.00512	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—GGT1—metabolic syndrome X	0.000192	0.00512	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—SLC2A4—metabolic syndrome X	0.000192	0.0051	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—MTNR1B—metabolic syndrome X	0.000188	0.00501	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—metabolic syndrome X	0.000187	0.00499	CbGpPWpGaD
Eprosartan—Nausea—Metformin—metabolic syndrome X	0.000186	0.0107	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—GGT1—metabolic syndrome X	0.000185	0.00494	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—EPHX2—metabolic syndrome X	0.000183	0.00487	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GHRL—metabolic syndrome X	0.000182	0.00486	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR1—metabolic syndrome X	0.000173	0.0046	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—AGT—metabolic syndrome X	0.000169	0.0045	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—AGT—metabolic syndrome X	0.000167	0.00445	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—metabolic syndrome X	0.000164	0.00436	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TGFB1—metabolic syndrome X	0.000163	0.00435	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PLA2G4A—metabolic syndrome X	0.000159	0.00422	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—metabolic syndrome X	0.000155	0.00412	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TNF—metabolic syndrome X	0.000153	0.00407	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—metabolic syndrome X	0.000151	0.00403	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—HTR2C—metabolic syndrome X	0.000146	0.0039	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—G6PC2—metabolic syndrome X	0.000145	0.00386	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—GHRL—metabolic syndrome X	0.000139	0.0037	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CCL2—metabolic syndrome X	0.000137	0.00366	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—metabolic syndrome X	0.000134	0.00357	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CNR1—metabolic syndrome X	0.000131	0.0035	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGT—metabolic syndrome X	0.000112	0.00298	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—MTNR1B—metabolic syndrome X	0.000106	0.00283	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CCL5—metabolic syndrome X	0.000102	0.00271	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—GCKR—metabolic syndrome X	9.93e-05	0.00265	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—MTNR1B—metabolic syndrome X	9.64e-05	0.00257	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—metabolic syndrome X	9.22e-05	0.00246	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS2—metabolic syndrome X	8.94e-05	0.00238	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—AGT—metabolic syndrome X	8.52e-05	0.00227	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—HTR2C—metabolic syndrome X	8.27e-05	0.0022	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—GCK—metabolic syndrome X	7.89e-05	0.0021	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—GHRL—metabolic syndrome X	7.84e-05	0.00209	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—CETP—metabolic syndrome X	7.61e-05	0.00203	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—HTR2C—metabolic syndrome X	7.51e-05	0.002	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CNR1—metabolic syndrome X	7.43e-05	0.00198	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GGT1—metabolic syndrome X	7.15e-05	0.0019	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—GHRL—metabolic syndrome X	7.12e-05	0.0019	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—EPHX2—metabolic syndrome X	7.12e-05	0.0019	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CCL2—metabolic syndrome X	7.02e-05	0.00187	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CNR1—metabolic syndrome X	6.75e-05	0.0018	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HDAC3—metabolic syndrome X	6.37e-05	0.0017	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—TGFB1—metabolic syndrome X	6.24e-05	0.00166	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC2A4—metabolic syndrome X	6.13e-05	0.00163	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CCL5—metabolic syndrome X	5.76e-05	0.00153	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MTNR1B—metabolic syndrome X	5.7e-05	0.00152	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—FABP4—metabolic syndrome X	5.69e-05	0.00152	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TRIB3—metabolic syndrome X	5.55e-05	0.00148	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RBP4—metabolic syndrome X	5.55e-05	0.00148	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—metabolic syndrome X	5.53e-05	0.00147	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—HSD11B1—metabolic syndrome X	5.39e-05	0.00144	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CCL5—metabolic syndrome X	5.23e-05	0.00139	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PLA2G4A—metabolic syndrome X	5.21e-05	0.00139	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—APOB—metabolic syndrome X	5.04e-05	0.00134	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOC3—metabolic syndrome X	4.92e-05	0.00131	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AGT—metabolic syndrome X	4.82e-05	0.00128	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—HDAC3—metabolic syndrome X	4.69e-05	0.00125	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—LPA—metabolic syndrome X	4.59e-05	0.00122	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G6—metabolic syndrome X	4.44e-05	0.00118	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HTR2C—metabolic syndrome X	4.44e-05	0.00118	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA5—metabolic syndrome X	4.4e-05	0.00117	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AGT—metabolic syndrome X	4.37e-05	0.00117	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CYBA—metabolic syndrome X	4.3e-05	0.00115	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—PPARA—metabolic syndrome X	4.25e-05	0.00113	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GHRL—metabolic syndrome X	4.21e-05	0.00112	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—TRIB3—metabolic syndrome X	4.09e-05	0.00109	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—APOA1—metabolic syndrome X	3.99e-05	0.00106	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CNR1—metabolic syndrome X	3.98e-05	0.00106	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—metabolic syndrome X	3.64e-05	0.000971	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOC3—metabolic syndrome X	3.62e-05	0.000965	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CCL2—metabolic syndrome X	3.6e-05	0.00096	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—FMO3—metabolic syndrome X	3.56e-05	0.000948	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CETP—metabolic syndrome X	3.52e-05	0.000937	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—metabolic syndrome X	3.37e-05	0.000897	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—SREBF1—metabolic syndrome X	3.27e-05	0.000871	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF2—metabolic syndrome X	3.26e-05	0.000868	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—HMGCR—metabolic syndrome X	3.18e-05	0.000847	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MLXIPL—metabolic syndrome X	3.17e-05	0.000845	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—EPHX2—metabolic syndrome X	3.17e-05	0.000845	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOB—metabolic syndrome X	3.16e-05	0.000843	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ALB—metabolic syndrome X	3.16e-05	0.000842	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCL5—metabolic syndrome X	3.09e-05	0.000823	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PLA2G4A—metabolic syndrome X	3.08e-05	0.00082	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LPL—metabolic syndrome X	3.02e-05	0.000805	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—G6PC2—metabolic syndrome X	2.98e-05	0.000794	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—metabolic syndrome X	2.83e-05	0.000755	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—metabolic syndrome X	2.74e-05	0.000731	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AGT—metabolic syndrome X	2.58e-05	0.000688	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—FABP4—metabolic syndrome X	2.53e-05	0.000675	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LEP—metabolic syndrome X	2.53e-05	0.000675	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOE—metabolic syndrome X	2.53e-05	0.000675	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOA1—metabolic syndrome X	2.5e-05	0.000667	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HSD11B1—metabolic syndrome X	2.4e-05	0.00064	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOB—metabolic syndrome X	2.33e-05	0.000621	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—metabolic syndrome X	2.27e-05	0.000604	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IRS1—metabolic syndrome X	2.26e-05	0.000602	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—metabolic syndrome X	2.22e-05	0.000593	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—INS—metabolic syndrome X	2.16e-05	0.000576	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—G6PD—metabolic syndrome X	2.14e-05	0.000571	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCL2—metabolic syndrome X	2.13e-05	0.000567	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CD36—metabolic syndrome X	2.11e-05	0.000563	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF1—metabolic syndrome X	2.09e-05	0.000557	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HDAC3—metabolic syndrome X	2.09e-05	0.000557	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LPA—metabolic syndrome X	2.04e-05	0.000544	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GCKR—metabolic syndrome X	2.04e-05	0.000544	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SERPINE1—metabolic syndrome X	1.99e-05	0.000529	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PLA2G6—metabolic syndrome X	1.98e-05	0.000527	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—metabolic syndrome X	1.96e-05	0.000523	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOA5—metabolic syndrome X	1.96e-05	0.000522	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—metabolic syndrome X	1.9e-05	0.000507	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOS3—metabolic syndrome X	1.9e-05	0.000505	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—metabolic syndrome X	1.86e-05	0.000497	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—metabolic syndrome X	1.84e-05	0.000491	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TRIB3—metabolic syndrome X	1.82e-05	0.000485	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NAMPT—metabolic syndrome X	1.63e-05	0.000435	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKT1—metabolic syndrome X	1.63e-05	0.000433	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—metabolic syndrome X	1.62e-05	0.000433	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LIPC—metabolic syndrome X	1.62e-05	0.000432	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GCK—metabolic syndrome X	1.62e-05	0.000432	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOC3—metabolic syndrome X	1.61e-05	0.00043	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6—metabolic syndrome X	1.6e-05	0.000426	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CETP—metabolic syndrome X	1.57e-05	0.000417	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SCARB1—metabolic syndrome X	1.5e-05	0.0004	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKT1—metabolic syndrome X	1.48e-05	0.000393	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	1.46e-05	0.000389	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SREBF1—metabolic syndrome X	1.46e-05	0.000388	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HMGCR—metabolic syndrome X	1.42e-05	0.000377	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GOT2—metabolic syndrome X	1.42e-05	0.000377	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	1.28e-05	0.00034	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCA1—metabolic syndrome X	1.26e-05	0.000336	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC2A4—metabolic syndrome X	1.26e-05	0.000336	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFB1—metabolic syndrome X	1.25e-05	0.000334	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GOT1—metabolic syndrome X	1.22e-05	0.000326	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GGT1—metabolic syndrome X	1.22e-05	0.000326	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOB—metabolic syndrome X	1.04e-05	0.000276	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PLA2G4A—metabolic syndrome X	1.01e-05	0.000269	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LPL—metabolic syndrome X	9.9e-06	0.000264	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6—metabolic syndrome X	9.45e-06	0.000252	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CD36—metabolic syndrome X	9.41e-06	0.000251	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPARA—metabolic syndrome X	8.75e-06	0.000233	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKT1—metabolic syndrome X	8.72e-06	0.000232	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AGT—metabolic syndrome X	8.47e-06	0.000226	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOE—metabolic syndrome X	8.3e-06	0.000221	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOA1—metabolic syndrome X	8.21e-06	0.000219	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPARG—metabolic syndrome X	7.23e-06	0.000193	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—INS—metabolic syndrome X	7.09e-06	0.000189	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALB—metabolic syndrome X	6.5e-06	0.000173	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NOS3—metabolic syndrome X	6.22e-06	0.000166	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS2—metabolic syndrome X	5.69e-06	0.000152	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AKT1—metabolic syndrome X	2.86e-06	7.62e-05	CbGpPWpGaD
